Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 9 | 2023 | 2155 | 1.520 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2024 | 488 | 1.350 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2023 | 278 | 1.320 |
Why?
|
| Tuberculosis | 4 | 2024 | 613 | 0.920 |
Why?
|
| Neonatology | 1 | 2023 | 50 | 0.860 |
Why?
|
| Antiprotozoal Agents | 1 | 2022 | 42 | 0.840 |
Why?
|
| Leishmaniasis | 1 | 2022 | 33 | 0.830 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2022 | 54 | 0.830 |
Why?
|
| Leishmania | 1 | 2022 | 34 | 0.830 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 68 | 0.810 |
Why?
|
| Apnea | 1 | 2021 | 36 | 0.770 |
Why?
|
| Cyanosis | 1 | 2021 | 43 | 0.770 |
Why?
|
| Maternal Health | 1 | 2020 | 17 | 0.730 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2020 | 26 | 0.720 |
Why?
|
| Eosinophilia | 1 | 2022 | 182 | 0.710 |
Why?
|
| Hypersensitivity | 1 | 2022 | 220 | 0.700 |
Why?
|
| Malaria | 1 | 2020 | 92 | 0.700 |
Why?
|
| Coinfection | 2 | 2020 | 200 | 0.670 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 411 | 0.670 |
Why?
|
| Hookworm Infections | 1 | 2020 | 124 | 0.670 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 241 | 0.660 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 311 | 0.610 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 295 | 0.610 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 705 | 0.580 |
Why?
|
| Community Health Workers | 1 | 2017 | 61 | 0.570 |
Why?
|
| Family | 1 | 2021 | 784 | 0.550 |
Why?
|
| Community Health Services | 1 | 2017 | 128 | 0.540 |
Why?
|
| Education, Distance | 1 | 2017 | 100 | 0.540 |
Why?
|
| Parents | 1 | 2023 | 1084 | 0.530 |
Why?
|
| Program Evaluation | 1 | 2017 | 602 | 0.490 |
Why?
|
| Anemia | 1 | 2020 | 727 | 0.480 |
Why?
|
| Health Personnel | 1 | 2019 | 652 | 0.460 |
Why?
|
| Telemedicine | 1 | 2017 | 555 | 0.370 |
Why?
|
| Social Stigma | 2 | 2021 | 74 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 3182 | 0.300 |
Why?
|
| Child | 10 | 2024 | 30568 | 0.280 |
Why?
|
| Sputum | 2 | 2024 | 157 | 0.270 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 606 | 0.230 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2024 | 1199 | 0.210 |
Why?
|
| BCG Vaccine | 2 | 2023 | 428 | 0.210 |
Why?
|
| Humans | 20 | 2024 | 270880 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 28 | 0.210 |
Why?
|
| Sensitivity and Specificity | 4 | 2024 | 5171 | 0.210 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2022 | 43 | 0.210 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2022 | 34 | 0.200 |
Why?
|
| Eosinophils | 1 | 2022 | 166 | 0.190 |
Why?
|
| Leukocyte Count | 1 | 2022 | 735 | 0.190 |
Why?
|
| Contact Tracing | 1 | 2021 | 62 | 0.180 |
Why?
|
| HIV | 2 | 2023 | 236 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2023 | 8699 | 0.180 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 54 | 0.180 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 75 | 0.180 |
Why?
|
| Ancylostomatoidea | 1 | 2020 | 60 | 0.180 |
Why?
|
| Anemia, Neonatal | 1 | 2020 | 8 | 0.180 |
Why?
|
| Adolescent | 7 | 2024 | 32770 | 0.180 |
Why?
|
| Feces | 1 | 2024 | 861 | 0.170 |
Why?
|
| Informed Consent | 1 | 2023 | 417 | 0.170 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 53 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5927 | 0.170 |
Why?
|
| Transgender Persons | 1 | 2020 | 61 | 0.170 |
Why?
|
| Phototherapy | 1 | 2020 | 83 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 354 | 0.170 |
Why?
|
| Viral Load | 1 | 2021 | 485 | 0.170 |
Why?
|
| Young Adult | 4 | 2024 | 22245 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2021 | 272 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 309 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 206 | 0.150 |
Why?
|
| Health Education | 1 | 2020 | 303 | 0.150 |
Why?
|
| Sexual Behavior | 1 | 2020 | 313 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 296 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2020 | 481 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 119 | 0.150 |
Why?
|
| Skin | 1 | 2022 | 1274 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 4499 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2021 | 513 | 0.140 |
Why?
|
| HIV-1 | 1 | 2020 | 639 | 0.130 |
Why?
|
| Pregnancy | 2 | 2020 | 8127 | 0.130 |
Why?
|
| Decision Making | 1 | 2023 | 1253 | 0.130 |
Why?
|
| Rural Population | 1 | 2017 | 292 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 2359 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 932 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2021 | 9475 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1611 | 0.090 |
Why?
|
| Female | 7 | 2024 | 149029 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 833 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2023 | 39865 | 0.090 |
Why?
|
| Rifampin | 2 | 2022 | 218 | 0.090 |
Why?
|
| Antitubercular Agents | 2 | 2022 | 349 | 0.080 |
Why?
|
| Adult | 4 | 2024 | 82036 | 0.080 |
Why?
|
| United States | 2 | 2022 | 15864 | 0.080 |
Why?
|
| Mozambique | 1 | 2024 | 27 | 0.060 |
Why?
|
| Tanzania | 1 | 2024 | 72 | 0.060 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 18 | 0.060 |
Why?
|
| Male | 4 | 2024 | 128463 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 146 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 124 | 0.050 |
Why?
|
| Peru | 1 | 2020 | 60 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2021 | 291 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2021 | 376 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 76 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 216 | 0.040 |
Why?
|
| Cough | 1 | 2021 | 125 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2020 | 103 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 368 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 105 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 247 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 749 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 77 | 0.040 |
Why?
|
| Child Behavior | 1 | 2021 | 248 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 334 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 574 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 1073 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2021 | 477 | 0.040 |
Why?
|
| Global Health | 1 | 2023 | 689 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 521 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 472 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 13420 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 1164 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 62051 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 5102 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2394 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 3051 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1253 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 1549 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 3403 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 9290 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 17059 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 90382 | 0.010 |
Why?
|